Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. develops fully human anti-thymocyte immunoglobulin and multi-specific human immunoglobulin G therapies for type 1 diabetes and other autoimmune diseases. Its lead program, SAB-142, is a disease-focused immunotherapy candidate for autoimmune type 1 diabetes, supported by the company’s transchromosomic cattle, or Tc-Bovine, production system for generating targeted hIgG antibodies.
Recurring news themes include SAB-142 clinical and mechanistic data, scientific conference presentations, financial results and business updates, and capital actions such as common stock and pre-funded warrant offerings that fund clinical development, manufacturing, regulatory activity and general corporate purposes.
SAB BIO (Nasdaq: SABS) reported Q2 2026 results and pipeline progress for lead candidate SAB-142 in type 1 diabetes. The registrational Phase 2b SAFEGUARD trial now has over 60 activated sites across the U.S., Australia, New Zealand, U.K. and EU, with Part B enrollment on track for completion in Q4 2026 and topline data expected in 2H 2027.
The Phase 3 PRISE-hATG study received a grant from Breakthrough T1D and will be co‑funded by SAB BIO, evaluating SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis. SAB BIO reported $208.0 million in cash, cash equivalents and investment securities at June 30, 2026, guiding operational runway through 2028. Q2 2026 R&D expenses were $16.2 million and G&A expenses were $7.2 million, with a net loss of $22.5 million. The company began construction of a second Tc‑Bovine farm to expand manufacturing capacity and was added to the Russell 3000 and Russell 2000 indexes.
SAB Biotherapeutics (Nasdaq:SABS) will release its second quarter 2026 financial results on the morning of Thursday, August 6, 2026, and will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.
The Q2 2026 earnings call, titled “SAB BIO’s Q2 2026 Earnings Call”, can be accessed via domestic dial-in at 1-800-343-4136, international dial-in at 1-203-518-9843, using Conference ID SABBIO. A replay of the audio webcast will be available afterward in the Investors & Media section of the company’s website at ir.sab.bio.
SAB Biotherapeutics (Nasdaq:SABS) and Breakthrough T1D announced a grant to support PRISE‑hATG, a clinical study of SAB‑142 in Stage 3 type 1 diabetes. The trial will enroll patients 100 days to 2 years from diagnosis to assess preservation of C‑peptide and immune modulation, extending SAB‑142 evaluation beyond early-stage disease and complementing the ongoing Phase 2b SAFEGUARD trial. SAB BIO will co‑fund the study.
SAB Biotherapeutics (Nasdaq:SABS) will present new data on its lead program SAB-142, a fully human multi-specific anti-thymocyte globulin for newly diagnosed Stage 3 type 1 diabetes, at ADA’s 2026 Scientific Sessions and the FOCIS 2026 Annual Meeting in June.
Presentations will cover safety, pharmacokinetics, immunogenicity, pharmacodynamics, mechanistic insights, and long-term repeat dosing, supporting the ongoing registrational Phase 2b SAFEGUARD study, with topline data expected in 2H 2027. Materials will be posted on SAB BIO’s website after the meetings.
SAB BIO (Nasdaq:SABS) reported Q1 2026 results and pipeline progress for SAB-142 in type 1 diabetes.
The Phase 2b SAFEGUARD trial continues site activation globally, with enrollment on track to complete by end-2026 and topline data expected in 2H 2027. Recent Phase 1 data showed C-peptide preservation and improved glycemic control in Stage 3 T1D.
The FDA confirmed C-peptide AUC may serve as a surrogate endpoint for accelerated approval. Cash and securities totaled $217.6 million, boosted by a $95 million public offering, providing runway through 2028. Q1 R&D was $13.4 million, G&A $6.6 million, and net loss $18.9 million. A multi-year manufacturing agreement with Emergent BioSolutions was also secured.
SAB Biotherapeutics (Nasdaq: SABS) will release first quarter 2026 financial results on the morning of Tuesday, May 12, 2026 and hold a conference call and webcast at 8:30 AM ET to discuss results and business updates.
Conference dial-in, international number, conference ID 13760144, and a replay will be available under the Investors & Media section at ir.sab.bio.
SAB BIO (Nasdaq: SABS) reported Phase 1 T1D cohort results showing C-peptide preservation in all four treated participants and a super responder profile in three of four at Day 120. Treated participants also showed CD4+ Tconv cell exhaustion and mean CGM time-in-range improvement from 73% to 85%.
The cohort included six adults (four treated, two placebo); endpoints were measured at End of Study Day 120. Data showed sustained immunomodulation without immunodepletion and no increase in exogenous insulin use.
SAB BIO (Nasdaq: SABS) will present additional clinical and mechanistic data for lead program SAB-142 at the 21st Immunology of Diabetes Society Congress, April 20-24, 2026, in Brisbane. Presentations include an oral symposium and multiple posters highlighting multi-specific binding and C-peptide findings. The SAFEGUARD study is actively enrolling with an anticipated topline readout in 2H 2027.
Presentation materials will be posted on the company website at the time of the conference.
SAB Biotherapeutics (Nasdaq: SABS) closed an underwritten public offering on March 19, 2026 of 19,324,677 shares of common stock and pre-funded warrants for up to 2,753,246 shares at a public offering price of $3.85 per share (pre-funded warrants at $3.8499).
Gross proceeds were approximately $85 million before fees. The company granted underwriters a 30-day option to buy up to 3,311,688 additional shares. Net proceeds will primarily fund continued development and trials of SAB-142, manufacturing, regulatory activities, and general corporate purposes.
SAB BIO (Nasdaq: SABS) priced an underwritten public offering to raise approximately $85 million in gross proceeds through the sale of 19,324,677 common shares and pre-funded warrants to purchase up to 2,753,246 shares.
The offering is expected to close on or about March 19, 2026, with a 30-day underwriter option to buy up to 3,311,688 additional shares; net proceeds will fund clinical development of SAB-142, manufacturing, regulatory and general corporate purposes.